# NEXT_SESSION.md — Session 84 Handoff
**Written:** 2026-05-27  
**Last commit:** `2c889eda61e3` (Session 83 — competitive_relevance + relevance_rationale restored in DCS)

---

## Session 83 Complete: competitive_relevance Restored

Option C executed exactly as specced in the Session 81 decision memo:

1. **ALTER TABLE** — Added `competitive_relevance` (text + CHECK constraint) and `relevance_rationale` (text) to `drug_competitive_scores`.

2. **Backfill** — 166 rows populated from `drug_area_scores` where `drug_id + context_id` matched `drug_id + area_id`. 87 DCS-only rows remain null (newer drugs, expected).

3. **Code change** — `_makeAreaPI` DCS select (line ~13614) now fetches `competitive_relevance,relevance_rationale`.

4. **UI validation** — All 4 area tabs show restored relevance badges, left-border color coding, secondary sort, and tooltip rationale. Zero console errors.

The strategic relevance layer is live in production. DAS has no remaining UI dependencies.

---

## Session 82 Complete: Partner Pill Co-Dev Inversion

Two fixes shipped (commit `7c6315305b`):

1. **erd-1 data fix** — `partner_company` cleared to null. Now falls through to `display_partner_name = "Earendil"`. HXN-1003 shows "w/ Earendil" on Sanofi's card.

2. **Co-dev inversion in `_genericDetailHTML`** — When self-attribution guard fires on `partner_company` AND drug originated elsewhere (`d.company_id ≠ prog.company_id`), derives pill from `d.entity_name` instead. Itepekimab now shows "w/ Regeneron" on Sanofi's card. Existing correct pills (duvakitug, HXN-1002, etc.) unaffected.

---

## Session 84 Options

No single P0 mandate. Three independent tracks, each bounded:

### Track A — disease_areas DB Teardown (Standalone DB session)

Code is clean (Session 80). Anytime you want to drop the table:

```sql
-- Step 1: Verify constraint names
SELECT conname, conrelid::regclass AS table_name
FROM pg_constraint
WHERE confrelid = 'public.disease_areas'::regclass AND contype = 'f';

-- Step 2: Drop FK constraints
ALTER TABLE public.area_metadata          DROP CONSTRAINT IF EXISTS area_metadata_area_id_fkey;
ALTER TABLE public.mechanism_status       DROP CONSTRAINT IF EXISTS mechanism_status_area_id_fkey;
ALTER TABLE public.competitive_landscapes DROP CONSTRAINT IF EXISTS competitive_landscapes_area_id_fkey;

-- Step 3: Drop the table
DROP TABLE public.disease_areas;
```

This is fully independent — does not require code changes.

### Track B — Dual-read harness decommission review

The five harnesses (`_runPhase4BDualRead`, `_runPhase4BTL1ADualRead`, `_runPhase4BTEDDualRead`, `_runPhase4BAtopyDualRead`, `_runPhase4BFcRNDualRead`) compare DCS `overlap` vs DAS baseline.

Decommission gate: 30+ days of clean matching logs from all five harnesses. Session 83 completed 2026-05-27 — earliest eligible review date: **2026-06-27**.

Do NOT decommission early. If log review is the Session 84 mandate, start by pulling the console log output from the deployed dashboard for each harness.

### Track C — Enrich the 87 null competitive_relevance rows

87 DCS rows (drugs added after the original DAS migration) have `competitive_relevance = null`. These show no badge and no border — correct behavior for un-enriched entries.

To fill: run `company_enrichment.py` against those drugs for their respective areas. The enrichment pipeline produces `competitive_relevance` values as part of normal enrichment output. Backfill script would then UPDATE DCS from the enrichment output.

Query to identify the 87 rows:
```sql
SELECT dcs.drug_id, dcs.context_id, d.name
FROM drug_competitive_scores dcs
LEFT JOIN drugs d ON d.id = dcs.drug_id
WHERE dcs.competitive_relevance IS NULL
ORDER BY dcs.context_id, d.name;
```

---

## Retirement Status Summary

### Tables: Retirement Readiness

| Table | Status | Next Step |
|---|---|---|
| `disease_areas` | **✅ Code-clean** | DB FK teardown (3 ALTER + DROP) — standalone DB session |
| `drug_area_scores` | **🟡 Near-ready** | Dual-read harness decommission (30+ days clean logs, earliest 2026-06-27) |
| `drug_areas` | **🔴 Blocked** | Active fallback in `_makeAreaPI` for il4ra/tslp/ted until Phase 5 activations |
| `area_metadata` | **✅ Keep permanently** | Migration tracking system |
| `legacy_area_ontology_map` | **✅ Keep permanently** | Bridge table for all Phase 3+ backfills |

### area_metadata current state

| area_id | retirement_status | Note |
|---|---|---|
| atopy | flag_activated | Phase 3 done |
| fcrn | flag_activated | Phase 3 done |
| igf1r | flag_activated | Phase 3 done |
| tl1a | flag_activated | Phase 3 done |
| ibd | flag_activated | Phase 3 done |
| il4ra | legacy_retained | biological reads still on drug_area_scores pending Phase 5 activation |
| ted | legacy_retained | biological reads still on drug_area_scores pending Phase 5 activation |
| tslp | legacy_retained | biological reads still on drug_area_scores pending Phase 5 activation |
| autoimmune | not_started | Preserved strategic view |
| respiratory | not_started | Preserved strategic view |
| tcell | not_started | Preserved platform view |

---

## Session 84 Constraints

Do NOT:
- Drop `drug_area_scores`
- Remove dual-read harnesses before 2026-06-27 log review
- Touch `drug_areas`
- Start Phase 5 activations for il4ra/tslp/ted

---

## Key Docs Written This Session

- `docs/drug_area_scores_option_c_execution.md` — Full SQL + row counts + UI validation + remaining blockers

## Known Good State

- Dashboard: live at GitHub Pages, commit `2c889eda61e3`
- `index.html`: zero active `disease_areas` DB reads; partner pill co-dev inversion complete; `competitive_relevance` + `relevance_rationale` live in DCS reads
- `drug_competitive_scores`: 253 rows — 166 with `competitive_relevance` populated, 87 null (enrichment queue)
- `drug_area_scores`: archival only — dual-read harness baseline, no production UI reads
- Phase 3 dual-filter: all 4 reads on `target_id OR area_id`
- Partner pill system: all known issues resolved
